BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1368 related articles for article (PubMed ID: 27756421)

  • 1. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
    Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
    Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.
    Florian H; Meier A; Gauthier S; Lipschitz S; Lin Y; Tang Q; Othman AA; Robieson WZ; Gault LM
    J Alzheimers Dis; 2016; 51(4):1237-47. PubMed ID: 26967214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer's disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil.
    Fullerton T; Binneman B; David W; Delnomdedieu M; Kupiec J; Lockwood P; Mancuso J; Miceli J; Bell J
    Alzheimers Res Ther; 2018 Apr; 10(1):38. PubMed ID: 29622037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.
    Rogers SL; Doody RS; Mohs RC; Friedhoff LT
    Arch Intern Med; 1998 May; 158(9):1021-31. PubMed ID: 9588436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study.
    Frölich L; Ashwood T; Nilsson J; Eckerwall G;
    J Alzheimers Dis; 2011; 24(2):363-74. PubMed ID: 21258153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
    Atri A; Frölich L; Ballard C; Tariot PN; Molinuevo JL; Boneva N; Windfeld K; Raket LL; Cummings JL
    JAMA; 2018 Jan; 319(2):130-142. PubMed ID: 29318278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donepezil for dementia due to Alzheimer's disease.
    Birks JS; Harvey RJ
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD001190. PubMed ID: 29923184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia.
    Haig GM; Pritchett Y; Meier A; Othman AA; Hall C; Gault LM; Lenz RA
    J Alzheimers Dis; 2014; 42(3):959-71. PubMed ID: 25024314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group.
    Rogers SL; Friedhoff LT
    Dementia; 1996; 7(6):293-303. PubMed ID: 8915035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL.
    Dichgans M; Markus HS; Salloway S; Verkkoniemi A; Moline M; Wang Q; Posner H; Chabriat HS
    Lancet Neurol; 2008 Apr; 7(4):310-8. PubMed ID: 18296124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study.
    Haig G; Wang D; Othman AA; Zhao J
    Neuropsychopharmacology; 2016 Nov; 41(12):2893-2902. PubMed ID: 27319970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial.
    Wilkinson D; Windfeld K; Colding-Jørgensen E
    Lancet Neurol; 2014 Nov; 13(11):1092-1099. PubMed ID: 25297016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Donepezil for vascular cognitive impairment.
    Malouf R; Birks J
    Cochrane Database Syst Rev; 2004; (1):CD004395. PubMed ID: 14974068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perspectives in the management of Alzheimer's disease: clinical profile of donepezil.
    Rogers SL
    Dement Geriatr Cogn Disord; 1998; 9 Suppl 3():29-42. PubMed ID: 9853200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease.
    Johannsen P; Salmon E; Hampel H; Xu Y; Richardson S; Qvitzau S; Schindler R;
    CNS Drugs; 2006; 20(4):311-25. PubMed ID: 16599649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donepezil for dementia due to Alzheimer's disease.
    Birks J; Harvey RJ
    Cochrane Database Syst Rev; 2006 Jan; (1):CD001190. PubMed ID: 16437430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.
    De Jesus Moreno Moreno M
    Clin Ther; 2003 Jan; 25(1):178-93. PubMed ID: 12637119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease.
    Burns A; Gauthier S; Perdomo C
    Int J Geriatr Psychiatry; 2007 Aug; 22(8):806-12. PubMed ID: 17199235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of donepezil in Alzheimer's disease - results from a multinational trial.
    Burns A; Rossor M; Hecker J; Gauthier S; Petit H; Möller HJ; Rogers SL; Friedhoff LT
    Dement Geriatr Cogn Disord; 1999; 10(3):237-44. PubMed ID: 10325453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 69.